Summit Therapeutics (SMMT) Total Liabilities: 2016-2025
Historic Total Liabilities for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to $69.5 million.
- Summit Therapeutics' Total Liabilities rose 6.98% to $69.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.5 million, marking a year-over-year increase of 6.98%. This contributed to the annual value of $46.8 million for FY2024, which is 62.63% down from last year.
- As of Q3 2025, Summit Therapeutics' Total Liabilities stood at $69.5 million, which was up 7.54% from $64.6 million recorded in Q2 2025.
- Summit Therapeutics' 5-year Total Liabilities high stood at $537.5 million for Q4 2022, and its period low was $22.1 million during Q3 2022.
- Over the past 3 years, Summit Therapeutics' median Total Liabilities value was $117.8 million (recorded in 2023), while the average stood at $95.3 million.
- Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 1,686.35% in 2022, then tumbled by 76.70% in 2023.
- Quarterly analysis of 5 years shows Summit Therapeutics' Total Liabilities stood at $30.1 million in 2021, then skyrocketed by 1,686.35% to $537.5 million in 2022, then crashed by 76.70% to $125.3 million in 2023, then crashed by 62.63% to $46.8 million in 2024, then increased by 6.98% to $69.5 million in 2025.
- Its Total Liabilities was $69.5 million in Q3 2025, compared to $64.6 million in Q2 2025 and $39.5 million in Q1 2025.